Key result
GLS detects cardiotoxicity months earlier than LVEF, showing ~2% reduction at 1-3 months.
Why the study?
Does global longitudinal strain (GLS) improve early detection of chemotherapy-induced cardiotoxicity compared to left ventricular ejection fraction (LVEF) in breast cancer patients undergoing chemotherapy?
Meta-Analysis
Does global longitudinal strain (GLS) improve early detection of chemotherapy-induced cardiotoxicity compared to left ventricular ejection fraction (LVEF) in breast cancer patients undergoing chemotherapy?
GLS provides superior temporal sensitivity and diagnostic accuracy compared to LVEF for early detection of chemotherapy-induced cardiotoxicity in breast cancer patients.
Answers are grounded in this paper and cite their sources.
Adopt GLS preferentially for cardiotoxicity screening in breast cancer; confirms superiority over isolated LVEF.
BACKGROUND: Anthracycline-induced cardiotoxicity is a major cause of morbidity in breast cancer survivors. Although left ventricular ejection fraction (LVEF) is the gold standard for monitoring cardiac function, it is often considered a late and insensitive marker of myocardial damage. New methods have emerged: global longitudinal strain (GLS) and cardiac magnetic resonance (CMR) derived parameters as potentially superior tools for detecting subclinical dysfunction. This study aimed to systematically compare the diagnostic accuracy and temporal sensitivity of GLS, LVEF, and CMR índices in the early detection of chemotherapy-induced cardiotoxicity. METHODS: A systematic review and meta-analysis of clinical studies was conducted to evaluate the outcomes and technical accuracy of the main methods for assessing cardiac function in breast cancer patients undergoing chemotherapy, using the PubMed, Web of Science, and Scopus databases. Twenty-nine studies were included in the systematic review and meta-analysis. RESULTS: The meta-analysis revealed a distinct temporal dissociation between methods. GLS detected a significant absolute reduction of 1.81% (95% CI: 1.14 - 2.49; z = 5.25, p < .001) as early as 1-3 months after treatment initiation. In contrast, LVEF showed a significant reduction of 3.59% only at mid-term follow-up (4-6 months), typically remaining within the range of clinical normality (>50%). The HSROC analysis for GLS (10 studies) demonstrated robust diagnostic performance, with an Area Under the Curve (AUC) of 0.818, a pooled sensitivity of 74.6% (95% CI: 64.8%-82.4%), and a specificity of 76.3% (95% CI: 68.2%-82.9%). CONCLUSION: Comparative analysis of data from our meta-analyses supports the recommendation of Global Longitudinal Strain (GLS) as the preferred method for screening for cardiotoxicity, over isolated assessment by Left Ventricular Ejection Fraction (LVEF).
No takes yet. Share an insight, caveat, or question.
Linhares et al. (2026) conducted a meta-analysis in Chemotherapy-induced cardiotoxicity in breast cancer. Global longitudinal strain (GLS) vs. Left ventricular ejection fraction (LVEF) was evaluated on Absolute reduction in cardiac function (absolute reduction 1.81%, 95% CI 1.14 - 2.49, p=< .001). Global longitudinal strain (GLS) detected a significant absolute reduction of 1.81% at 1-3 months, earlier than LVEF which showed reduction only at 4-6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: